Trial Profile
A Phase II Trial of Radiation Therapy Combined With Iressa in Patients With Locally Advanced Non-small Cell Lung Cancer With Harboring Active EGFR Mutations
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2022
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 01 Aug 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 13 Jul 2011 New trial record